Fig. 1.

Change from baseline in pre-bronchodilator FEV₁ over 52 weeks in patients grouped by (a) disease duration, (b) baseline post-bronchodilator FEV₁ reversibility, and (c) post-bronchodilator FEV₁/FVC ratio. “Number of patients” indicates the number of patients with available data at a given time point. Patients who received at least one dose of tezepelumab or placebo with at least one change from baseline assessment were included in the model. Data are adjusted means and 95% CIs. CI confidence interval, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity, Q4W every 4 weeks